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Background: There is a widespread assumption that risk prediction is the major driver of customer interest in
personal genomic testing (PGT). However, some customers may also be motivated by finding out whether their
existing diseases have a genetic etiology. We evaluated the impact of an existing medical diagnosis on customer
interest in condition-specific results from PGT.
Methods: Using a prospective online survey of PGT customers, we measured customer interest prior to receiving
PGT results for 11 health conditions, and examined the association between interest and personal medical history
of these conditions using logistic regression.
Results: We analyzed data from 1,538 PGT customers, mean age 48.7 years, 61 % women, 90 % White, and 47 %
college educated. The proportion of customers who were ‘very interested’ in condition-specific PGT varied
considerably, from 28 % for ulcerative colitis to 68% for heart disease. After adjusting for demographic and
personal characteristics including family history, having a diagnosis of the condition itself was significantly
associated with interest in genetic testing for risk of that condition, with odds ratios ranging from 2.07 (95 % CI 1.28-3.37)
for diabetes to 19.99 (95 % CI 4.57-87.35) for multiple sclerosis.
Conclusions: PGT customers are particularly interested in genetic markers for their existing medical conditions,
suggesting that the value of genetic testing is not only predictive, but also explanatory.Background
Direct-to-consumer (DTC) personal genomic testing
(PGT) continues to be controversial, with debate center-
ing on the analytical validity of PGT results, and the
clinical validity and utility of returning this type of infor-
mation to individual customers without involvement of
healthcare providers [1–5]. Critics of PGT have cau-
tioned that customers may misinterpret their genetic test
results, leading to harm or unnecessary medical expend-
iture [1, 6]. However, other commentators have empha-
sized the potential for PGT to raise awareness of genetic
disease predisposition and prompt lifestyle changes to
mitigate disease risk; ultimately reducing the burden posed
by these conditions on the healthcare system [7, 8].* Correspondence: rcgreen@genetics.med.harvard.edu
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perience has focused primarily on the psychological and
behavioral effects of PGT [9, 10]. Somewhat less atten-
tion has been paid to the motivations of individuals who
seek PGT. In the few studies that have investigated this
topic, the predominant drivers of interest in PGT have
been identified as curiosity and gaining insight into
future disease risk [10–12]. However, alternative motiva-
tions may also exist: for example, in two qualitative
studies, we found that overweight and obese individuals
sought genetic testing in part to obtain an explanation
for their condition [13, 14]. As these findings were in a
small sample, focused on only one health condition
(obesity) and did not specifically pertain to DTC testing,
it is not clear whether they could have application to the
wider PGT consumer population.
In the traditional clinic setting, genetic testing related
to a current diagnosis is frequently ordered for the pur-
pose of identifying or confirming etiology, guiding treat-
ment, determining prognosis, or providing recurrenceis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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titative study has investigated the effect of an existing
medical diagnosis on interest in obtaining disease-
specific genetic risk information in the DTC PGT set-
ting. Using data from the Impact of Personal Genomics
(PGen) Study, [15] a longitudinal survey study of cus-
tomers from 23andMe, Inc. [16] and Pathway Genomics,
[17] we evaluated the association between personal
history of a disease, family history of a disease, and
interest in PGT results for that disease. Defining per-
sonal and demographic correlates of interest in
obtaining PGT is important because these could in-
fluence subsequent affective and behavioral responses
to test results [10, 12]. Based on previous findings
related to interest in genetic testing for obesity risk
[13, 14], we hypothesized that PGT customers would
be particularly interested in receiving genetic risk in-
formation for a health condition they already had,
possibly even more than for a condition they might
develop in the future.
Materials and methods
Study design
Data for our analysis were obtained from the Impact of
Personal Genomics (PGen) Study, a longitudinal study
of DTC PGT customers from 23andMe and Pathway
Genomics. The PGen Study protocol was designed and
administered by academic researchers at Harvard
Medical School/Brigham and Women’s Hospital and
the University of Michigan School of Public Health,
in partnership with scientists from the two PGT
companies, and independent survey design experts
from SoundRocket (formerly Survey Sciences Group,
Ann Arbor, MI, USA). Details of this academia-
industry collaboration, and the analytical design and
administration of the PGen Study, have been reported
previously [15, 18].
Briefly, new DTC PGT customers of 23andMe and
Pathway Genomics were recruited via email between
March and July 2012. Survey data were collected online
at three time points: first after customers purchased
PGT, but before they received their results (baseline;
BL), then approximately 2 weeks post results (2W), and
finally approximately 6 months post results (6M). A total
of 1,648 participants completed the BL survey. PGT re-
sults were returned to customers as per standard com-
pany practice, and then linked to survey data at the end
of survey administration. The PGen Study was approved
by the Partners Human Research Committee and the
University of Michigan Health Sciences and Behavioral
Sciences Institutional Review Board, and informed con-
sent was obtained electronically from each participant
prior to enrollment. The research conformed to the
Helsinki Declaration.Outcome variables
For each condition addressed in the results report, cus-
tomers of 23andMe and Pathway were provided with a
personal risk estimate based on one or more single nu-
cleotide polymorphism (SNP) markers. Interest in learn-
ing their risk estimate for each of 24 conditions was
evaluated at BL with the multiple-choice question: ‘How
interested are you in learning about your genetic risk for
each of these diseases’, for which response options were:
‘not at all interested/somewhat interested’, and ‘very
interested’.
Whether or not a customer had ever had a diagnosis
of each condition for which a risk estimate could be ob-
tained from PGT was evaluated at BL with the question:
‘Has a doctor ever told you that you have one of the
following medical conditions’. Using a hierarchical
question structure, participants were first presented
with eight broad disease categories (neurological, psy-
chiatric, gastrointestinal, heart, eye, diabetes, obesity,
cancer), and then a choice of specific conditions for
any selected category (for example, diabetes: Type 1
diabetes; Type 2 diabetes). They could select as many
conditions as applicable.
Family history for each of the 24 conditions was evalu-
ated at BL with the question: ‘Have any of your blood
relatives (a parent, brother or sister, child, grandparent,
aunt, uncle, or first cousin) ever had any of the following
conditions’. The same hierarchical question structure
(broad then specific) was used to identify family history.
The following demographic characteristics were re-
corded at BL: age, gender, race/ethnicity (six race cat-
egories, plus Hispanic/Latino ethnicity option), and
highest education level (11 categories). Current health
status was assessed at BL with one multiple-choice ques-
tion from the Control Preference Scale [19]: ‘In general,
would you say your health is: [excellent/very good/good/
fair/poor]’. State anxiety, which may affect health infor-
mation seeking, [20] was evaluated at BL with the two-
item brief Generalized Anxiety Disorder screen (GAD-2)
[21]. Multiple-choice responses to the two questions
(‘Over the past two weeks, how often have you felt ner-
vous, anxious, or on edge’ and ‘Over the past two
weeks, how often have you been unable to stop or con-
trol worrying’) used response options from ‘not at all’
(scored 0) to ‘nearly every day’ (scored 3). A summed
score of 4 or more represents a positive screen for gen-
eralized anxiety or panic disorder.
Statistical analyses
Our analysis used survey data from only the BL survey,
which comprised 240 questions, including demographic
characteristics, interest, and motivations for undergoing
PGT, and personal and family history. For the purposes
of our analysis, we restricted the PGen Study dataset to
Table 1 Participant characteristics (n = 1,538)
Variable Frequency
n (%)
Mean age (SD; range) 48.7 (15.5; 20–95)
Female 936 (60.9)
Non-White race 154 (10.0)
Hispanic/Latino ethnicity 84 (5.5)
23andMe customers 978 (63.6)
Positive GAD-2 screen for anxiety/panic disorder 163 (10.6)
Highest level of education
< College degree 340 (22.1)
College degree 472 (30.7)
Some graduate school 531 (34.5)





Very good 604 (39.3)
Excellent 231 (15.0)
GAD-2, Generalized Anxiety Disorder – 2 Item Scale; SD, standard deviation
Meisel et al. Genome Medicine  (2015) 7:74 Page 3 of 7the 1,648 participants who completed the BL survey
prior to viewing their results. We further excluded par-
ticipants with missing data on the predictor variables.
Descriptive statistics were computed to summarize the
baseline demographic characteristics of the study sam-
ple, interest in PGT results for each condition, and the
frequency of personal and family history of each condi-
tion. Descriptive statistics were also computed within
each company-specific sample to investigate differences
in characteristics between participants recruited from
each PGT company.
Of the 24 conditions for which customers of both
companies were provided with PGT results, 13 condi-
tions (age-related macular degeneration, Alzheimer’s dis-
ease, amyotrophic lateral sclerosis, blood clotting, breast
cancer, celiac disease, chronic kidney disease, colorectal
cancer, glaucoma, leukemia, lung cancer, Parkinson’s
disease, and prostate cancer) had a reported frequency
of <2%. These conditions were excluded from analysis
because of the small sample sizes. Results for the follow-
ing 11 conditions are reported here: asthma, bipolar
disorder, type 2 diabetes, heart disease (specifically cor-
onary artery disease), high cholesterol, multiple sclerosis,
obesity, osteoarthritis, rheumatoid arthritis, skin cancer,
and ulcerative colitis.
We used multivariate logistic regression to evaluate
associations between personal history of a condition,
family history of a condition, and interest in condition-
specific PGT results. In all models, we dichotomized the
outcome as ‘very interested’ vs. ‘somewhat/not at all in-
terested’. We used binary variables for ‘ever’ personal or
family history of each condition, and models were ad-
justed for variables likely to be associated with interest
based on prior work [22, 23], including age (continuous),
gender (male vs. female), race (White vs. non-White),
Hispanic/Latino ethnicity (yes vs. no), education (four
categories, as described in Table 1), positive GAD-2
screen for anxiety/panic disorder (yes vs. no), ever his-
tory of any other condition (yes vs. no), and current
health status (five categories, as reported). Finally, all
analyses were adjusted for PGT company (23andMe vs.
Pathway) to account for the different recruitment strat-
egies employed by each company and the resulting dif-
ferences in demographic and motivational characteristics
within the company-specific sub-groups. Data were ana-
lyzed using the Statistical Package for Social Sciences,
SPSS version 21.0 (Chicago, IL, USA).
Results
Of the 1,648 participants who completed the BL survey
prior to viewing their results, 110 (6.7 %) were excluded
due to missing data necessary for our analyses. Demo-
graphic characteristics of the remaining 1,538 partici-
pants included in our analyses are shown in Table 1.Compared to participants recruited from 23andMe, par-
ticipants from Pathway were more likely to be women
(67.3 % vs. 57.3 %, P <0.001); to have a positive screen
for anxiety at baseline (13.8 % vs. 8.8 %, P = 0.002); to
report lower levels of education (global F-test P <0.001)
and lower self-reported health (global F-test P <0.001);
and tended to be younger (mean age = 44.3 vs. 51.2,
P <0.001) (Additional file 1: Table S1). The propor-
tion of participants who reported that they were ‘very
interested’ in PGT results for each of the 11 condi-
tions ranged from 28.0 % (ulcerative colitis) to 68.1 %
(heart disease) (Fig. 1). A majority of participants were
very interested in results for high cholesterol, type 2 dia-
betes, skin cancer, and heart disease. Only 227 partici-
pants (14.8 %) were very interested in PGT for all 11
conditions, and even fewer (n = 29, 1.9 %) stated that
they were not at all interested in PGT for any of the 11
conditions. Figure 1 shows the proportion of participants
who were very interested in PGT results for each condi-
tion, stratified by personal diagnosis status. Across all
conditions, participants who reported a personal diagno-
sis of a given condition were more likely to be very inter-
ested in PGT results for that condition than participants
who did not report it. Condition-specific interest was
consistently higher among participants from Pathway,
but no clear pattern of differences in frequency of per-
sonal diagnosis and family history was noted across com-
panies (Additional file 1: Table S2).
Fig. 1 Proportion of individuals ‘very interested’ in genetic testing for a condition they already have versus those without a diagnosis of the condition
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sonal diagnosis of each of the 11 conditions ranged from
2.0 % (heart disease, ulcerative colitis) to 36.2 % (high
cholesterol) (Table 2). Only five conditions (asthma,
obesity, diabetes, osteoarthritis, high cholesterol) had a
frequency greater than 15 %. The frequency of reported
family history of each condition was typically higher,
ranging from 6.9 % (multiple sclerosis) to 68.6 % (high
cholesterol) (Table 2).
Results of the logistic regression analyses are presented
in Table 2. After adjustment for age, gender, race, ethni-
city, education, anxiety, PGT company, and diagnosis of
any other condition, both personal and family history of
a condition were significantly associated in all cases with
interest in PGT results for that condition. Odds ratios
for the effect of a personal history on interest ranged
from 2.07 (diabetes) to 19.99 (multiple sclerosis), while
odds ratios for the effect of a family history on interest
were in most cases smaller, ranging from 1.55 (rheumatoid
arthritis) to 4.14 (multiple sclerosis).
Discussion
Using baseline data from the PGen Study, we demon-
strated that consumer interest in genetic risk information
from PGT is independently associated both with having a
family history of the condition and with having the condi-
tion itself. This finding is surprising because the emphasis
of PGT marketing and discussion is typically focused on
predicting future health risks. Although earlier work has
often focused on the role of family history of a disease as
motivation to obtain PGT [11, 12], the notion that DTC
customers could be most interested in information on the
etiology of their own disease condition has not yet been
raised in discussions about the utility of PGT.Comparisons of odds ratios across conditions encour-
age the speculation that rarer conditions, and conditions
without firmly established etiology (such as multiple
sclerosis, bipolar disorder, and ulcerative colitis), could
evoke more interest in a genetic explanation than more
common conditions (obesity, elevated cholesterol, and
heart disease). Thus, it is possible that individuals who
decide to purchase PGT anticipate deriving psycho-
logical benefit from information that might appear to
shed light on the etiology of a disease they already
have. Even for a condition that is as common as obes-
ity, and where strong public beliefs about etiology
exist, overweight participants in our prior qualitative
studies described relief of guilt and self-blame after
learning about their increased genetic risk of obesity,
without any negative impact on motivation to ‘battle
their biology’ [13, 14]. These findings match those
from the area of genetic testing for mental health con-
ditions, which also show that awareness of genetic risk
may help to relieve rumination about causes of mental
illness [24]. Alternatively, it is possible that individuals
want to receive information on a genetic contribution
to their personal illness in order to share this informa-
tion with children or other family members for the
purposes of risk evaluation and disease prevention [11, 12].
A third possibility is that customers believe knowledge
about the underlying genetics of a condition could im-
prove treatment outcomes, perhaps through pharma-
cogenomics. Since this is the first large-scale study to
suggest an explanatory value of PGT for an existing
condition, the findings need to be replicated and it will
be important to carry out further qualitative and quan-
titative research to explore the reasons behind this
phenomenon.
Table 2 Individuals with personal diagnosis and family history
of each condition, and logistic regression examining the
association with interest among customers
Condition n (%) ORa 95 % CI P value
Ulcerative colitis
No diagnosis/No FH 1
Diagnosis 31 (2.0) 6.83 2.21-21.12 0.001
FHx 93 (9.0) 2.54 1.59-4.30 <0.001
Asthma
No diagnosis/No FH 1
Diagnosis 341 (22.2) 2.86 1.66-4.90 <0.001
FHx 552 (36.5) 1.82 1.43-2.31 <0.001
Bipolar disorder
No diagnosis/No FH 1
Diagnosis 48 (3.1) 13.54 1.74-105.15 0.013
FHx 226 (19.9) 3.23 2.29-4.54 <0.001
Multiple sclerosis
No diagnosis/No FH 1
Diagnosis 62 (4.0) 19.99 4.57-87.35 <0.001
FHx 76 (6.9) 4.14 2.40-7.00 <0.001
Obesity
No diagnosis/No FH 1
Diagnosis 350 (22.8) 2.35 1.17-5.4.71 0.016
FHx 750 (49.4) 1.70 1.36-2.12 <0.001
Rheumatoid arthritis
No diagnosis/No FH 1
Diagnosis 63 (4.1) 3.87 1.97-7.60 <0.001
FHx 199 (15.0) 1.55 1.21-1.96 0.005
Osteoarthritis
No diagnosis/No FH 1
Diagnosis 353 (23.0) 2.51 1.63-3.87 <0.001
FHx 593 (44.7) 1.49 1.17-1.90 0.001
High cholesterol
No diagnosis/ No FH 1
Diagnosis 556 (36.2) 2.98 1.86-4.76 <0.001
FHx 1039 (68.6) 1.64 1.31-2.06 <0.001
Diabetes
No diagnosis/No FH 1
Diagnosis 94 (6.1) 2.07 1.28-3.37 0.003
FHx 604 (39.3) 2.43 1.97-2.99 <0.001
Skin cancer
No diagnosis/ No FH 1
Diagnosis 36 (2.3) 4.49 1.47-13.69 0.008
FHx 282 (18.3) 2.36 1.74-3.20 <0.001
Table 2 Individuals with personal diagnosis and family history
of each condition, and logistic regression examining the
association with interest among customers (Continued)
Heart disease (coronary artery)
No diagnosis/No FH 1
Diagnosis 31 (2.0) 3.99 1.18-2.17 0.018
FHx 575 (56.7) 2.10 1.66-2.62 <0.001
aThe model for each condition includes history of personal diagnosis and family
history of that condition, and is adjusted for age, sex, race, ethnicity, education,
company from which the test was purchased along with self-reported health and
diagnosis of any other medical condition
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studies that have demonstrated that genetic testing for a
particular condition is motivated by family history of
that condition [10, 12]. For example, a systematic review
of 23 studies investigating uptake for breast cancer
predictive genetic testing, either through actual up-
take or anticipated uptake in hypothetical scenarios,
found that individuals with a family history of cancer
were twice as likely to have genetic testing for cancer
risk as those without a family history [25]. Likewise,
in a population-based survey, family history of heart
disease was highly predictive of interest in genetic
testing for heart disease [26].
This analysis had several strengths. The extensive in-
formation on demographics and family history collected
in the PGen Study allowed us to control for possible
confounding by the factors most commonly cited as hav-
ing an impact on interest in genetic testing. The number
of participants with each diagnosis was high enough to
conduct the analysis, and we observed the effect regard-
less of condition, which increased our confidence in the
validity of the findings. However, the study also had im-
portant limitations. Due to the small numbers of partici-
pants with a prior diagnosis for some of the diseases,
confidence intervals were very wide for some conditions.
Further research is needed to clarify whether the effect
will also be observed in samples where a greater propor-
tion has been diagnosed. Interest in PGT for specific
conditions was only assessed with a simple three-point
ordinal scale, without considering follow-up questions
about its motivations or origins of interest. Future re-
search could include questions that examine this topic
in greater detail; for example, by using open-ended ques-
tions. For the current analyses, we only looked at ‘ever’
diagnosis of a condition, not whether customers were
currently suffering with this condition. This may explain
why a large proportion of participants reported both
‘excellent’ health, and having a medical diagnosis. Since
a subset of PGen Study participants were drawn from a
health-based social networking site, it is likely that these
participants were particularly interested in exploring
their health condition in more depth than the average
Meisel et al. Genome Medicine  (2015) 7:74 Page 6 of 7person. Because participation was voluntary and part of
a research study, our participants may differ from the
typical PGT customer, and will certainly differ from the
general population. Finally, all of our data were collected
using self-report, which has been shown to vary in ac-
curacy [27] and may introduce an element of bias.
Conclusions
In conclusion, data from the PGen Study showed that a
prior diagnosis of a disease is significantly associated with
interest in PGT for that condition, even after adjusting for
variables commonly associated with increased interest in
genetic testing; including family history. This correlation
with interest in genetic testing has not been previously de-
scribed in research on the benefits and harms of PGT, and
it may be an important factor in evaluating the clinical and
personal utility of personal genomic testing.
Additional file
Additional file 1: Tables S1 and S2 contain descriptive statistics
stratified by personal genomic testing company. (DOCX 19 kb)
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